IRVINE, Calif.--(BUSINESS WIRE)--Aug 8, 2019--

Endologix, Inc. (the “Company”) (NASDAQ:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced financial results for the second quarter ended June 30, 2019.

“We are pleased with our second quarter results, as stronger execution led to a sequential improvement in revenue,” commented John Onopchenko, Chief Executive Officer of Endologix, Inc. “Our culture of accountability is yielding tangible results, and our team continues to steadily leverage a growing body of clinical evidence to rebuild credibility in the marketplace. We are excited about the progress we made during the first half of the year against both our near- and long-term targets, providing us confidence in our full-year outlook. We will remain focused on execution as we continue to take meaningful and necessary steps to position the Company for sustainable long-term success.”

Financial Results

Global revenue in the second quarter of 2019 was $36.2 million, a 19.0% decrease from $44.7 million in the second quarter of 2018. U.S. revenue in the second quarter of 2019 was $24.0 million, a 19.9% decrease from U.S. revenue of $30.0 million in the second quarter of 2018. International revenue was $12.2 million, a 17.1% decrease from International revenue of $14.8 million in the second quarter of 2018. On a constant currency basis, second quarter 2019 International revenue decreased 14.8% over the second quarter of 2018.

Gross profit was $23.0 million in the second quarter of 2019, representing a gross margin of 63.4%. This compares to a gross profit of $29.6 million, or a gross margin of 66.2%, in the second quarter of 2018 as lower sales volumes more than offset operational improvements.

Total operating expenses decreased 27.2% to $32.9 million in the second quarter of 2019, compared to $45.1 million in the second quarter of 2018.

Net loss for the second quarter of 2019 was $27.1 million, or $(1.50) per share, compared to a net loss of $23.9 million, or $(2.83) per share, a year ago. Adjusted Net Loss (non-GAAP, defined below) totaled $6.6 million, compared to an Adjusted Net Loss of $15.6 million for the second quarter of 2018. Adjusted EBITDA (non-GAAP, defined below) loss totaled $5.6 million for the second quarter of 2019, compared to Adjusted EBITDA loss of $9.3 million for the second quarter of 2018.

Total cash, cash equivalents, and restricted cash were $52.1 million as of June 30, 2019.

Financial Guidance

The Company reaffirms its previously issued annual guidance and continues to expect 2019 revenue of at least $140 million. The Company anticipates revenue for the third quarter ending September 30, 2019 in the range of $35 million to $37 million. The Company continues to expect 2019 operating expenses in the range of $130 million to $140 million.

Conference Call Information

The Company's management will host a conference call today at 4:30 p.m. ET (1:30 p.m. PT) to discuss its second quarter 2019 results.

To participate in the conference call, dial 877-407-9716 (domestic) or +1 201-493-6779 (international) and refer to the passcode 13692632.

This conference call will also be webcast and can be accessed from the “Investors” section of the Company’s website at www.endologix.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.

A recording of the call will also be available from 7:30 p.m. ET on Thursday, August 8, 2019, until 11:59 p.m. ET on Thursday, August 15, 2019. To hear this recording, dial 844-512-2921 (domestic) or +1 412-317-6671 (international) and enter the passcode 13692632.

About Endologix, Inc.

The Company develops and manufactures minimally invasive treatments for aortic disorders. The Company's focus is in endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once an AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 80%, making it a leading cause of death in the U.S. For more information, visit www.endologix.com.

The Nellix ® EndoVascular Aneurysm Sealing System has obtained CE Mark in the EU and is only approved as an investigational device in the United States. The Ovation Alto ® System is only approved as an investigational device and is not currently approved in any market.

Cautions Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can generally be identified by the use of words such as “anticipate,” “expect,” “could,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” “continue,” “outlook,” “guidance,” “future,” other words of similar meaning and the use of future dates. Forward-looking statements include all statements other than statements of historical fact contained in this press release, including statements regarding the Company’s confidence in its ability to accomplish its goals for the rest of 2019; the Company’s leveraging of clinical evidence to rebuild credibility in the marketplace; the Company’s focus on execution as it continues to take steps to position itself for sustainable long-term success; and the Company’s Q3 2019 and FY 2019 revenue guidance and its anticipated FY 2019 operating expense, the accuracy of which are necessarily subject to risks and uncertainties that may cause the Company’s actual results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ materially and adversely from anticipated results include continued market acceptance, endorsement and use of the Company’s products, the Company’s continued compliance with its financial covenants and other operating restrictions under its lending facilities, the Company’s ability to access the capital markets on terms acceptable to it or at all, the Company’s abilities to service its indebtedness and to satisfy and discharge its indebtedness as such indebtedness comes due, the success of clinical trials relating to the Company’s products, product research and development efforts, uncertainty in the process of obtaining and maintaining regulatory approval for the Company’s products, the Company s ability to protect its intellectual property rights and proprietary technologies, the Company’s ability to retain its key executive, sales and other personnel, and other economic, business, competitive, and regulatory factors. Forward-looking statements represent our management’s current expectations and predictions about trends affecting our business and industry and are based on information available as of the time such statements are made. The forward-looking statements contained in this press release speak only as of the date of this press release. The Company undertakes no obligation to update any forward- looking statements contained in this press release to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events. Please refer to the Company’s filings with the Securities and Exchange Commission including its Annual Report on Form 10-K for the year ended December 31, 2018 and subsequent Quarterly Reports on Form 10-Q for more detailed information regarding these risks and uncertainties and other factors that may cause actual results to differ materially from those expressed or implied in the forward-looking statements.

Discussion of Non-GAAP Financial Measures

The Company’s management believes that the non-GAAP measures of (1) “Adjusted Net Income (Loss)” and (2) “Adjusted EBITDA” enhance an investor’s overall understanding of the Company’s financial and operating performance and its future prospects by (i) being more reflective of core operating performance and (ii) being more comparable with financial results over various periods. These measures, when used in conjunction with related financial measures calculated in accordance with generally accepted accounting principles in the United States (“GAAP”), provide investors with an additional financial analytical framework that may be useful in assessing the Company’s financial condition and results of operations. The Company’s management uses these financial measures for strategic decision making, forecasting future financial results, and evaluating current period financial and operating performance. The presentation of non-GAAP financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP. Furthermore, these measures are not intended to be liquidity measures. Other companies, including other companies in the Company’s industry, may not use these measures or may calculate these measures differently than the Company does, limiting their usefulness as comparative measures. The Company intends to calculate these non-GAAP financial measures in a consistent manner from period to period. A reconciliation of each of the non-GAAP financial measures to the most directly comparable GAAP measures has been provided under the heading “Non-GAAP Reconciliations” in the financial statement tables attached to this press release.

Adjusted Net Income (Loss) Definition:

(1) “Adjusted Net Income (Loss)” is a non-GAAP measure defined by the Company as net income (loss) under GAAP, excluding (to the extent relevant in a particular reporting period): (i) restructuring and other transition costs; (ii) contract termination, product withdrawal and business acquisition expenses; (iii) legal settlement costs; (iv) business development expenses, including licensing costs related to research and development activities; (v) inventory step-up amortization; (vi) interest expense; (vii) foreign currency loss (gain); (viii) fair value adjustment to Nellix ® contingent consideration liability; (ix) fair value adjustment of derivative liabilities; and (x) loss on debt extinguishment.

In the three and six months ended June 30, 2019 and 2018, this GAAP adjustment to net loss specifically represents: (i) the fair value adjustment to Nellix ® contingent consideration liability; (ii) interest expense; (iii) foreign currency losses; (iv) restructuring and other transition costs; (v) fair value adjustment of derivative liabilities; and (vi) loss on extinguishment of debt.

Adjusted EBITDA Definition:

(2) “Adjusted EBITDA” is a non-GAAP measure defined by the Company as “Adjusted Net Income (Loss)” excluding income tax (benefit) expense, depreciation and amortization expense, and stock-based compensation expense.

ENDOLOGIX, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

Unaudited

(In thousands, except per share amounts)

 

Three Months Ended

 

Six Months Ended

 

June 30,

 

June 30,

 

2019

 

2018

 

2019

 

2018

Revenue

 

 

 

 

 

 

 

U.S.

$

24,013

 

 

$

29,986

 

 

$

46,798

 

 

$

59,361

 

International

12,225

 

 

14,754

 

 

25,046

 

 

27,663

 

Total Revenue

36,238

 

 

44,740

 

 

71,844

 

 

87,024

 

Cost of goods sold

13,254

 

 

15,136

 

 

25,661

 

 

29,094

 

Gross profit

$

22,984

 

 

$

29,604

 

 

$

46,183

 

 

$

57,930

 

Operating expenses:

 

 

 

 

 

 

 

Research and development

4,355

 

 

6,244

 

 

9,142

 

 

11,743

 

Clinical and regulatory affairs

3,647

 

 

3,728

 

 

7,432

 

 

7,299

 

Marketing and sales

15,920

 

 

21,116

 

 

32,706

 

 

42,841

 

General and administrative

8,929

 

 

14,022

 

 

18,345

 

 

24,391

 

Restructuring costs

 

 

 

 

419

 

 

233

 

Total operating expenses

32,851

 

 

45,110

 

 

68,044

 

 

86,507

 

Loss from operations

(9,867

)

 

(15,506

)

 

(21,861

)

 

(28,577

)

Other income (expense)

(9,336

)

 

(6,544

)

 

(17,508

)

 

(11,985

)

Change in fair value of contingent consideration related to
acquisition

(300

)

 

(1,800

)

 

(100

)

 

(700

)

Loss on debt extinguishment

(11,756

)

 

 

 

(11,756

)

 

(2,270

)

Change in fair value of derivative liabilities

872

 

 

 

 

(1,151

)

 

 

Total other expense, net

(20,520

)

 

(8,344

)

 

(30,515

)

 

(14,955

)

Net loss before income taxes

$

(30,387

)

 

$

(23,850

)

 

$

(52,376

)

 

$

(43,532

)

Income tax benefit (expense)

3,253

 

 

(26

)

 

3,214

 

 

(111

)

Net loss

$

(27,134

)

 

$

(23,876

)

 

$

(49,162

)

 

$

(43,643

)

Other comprehensive income (loss) foreign currency
translation

588

 

 

(552

)

 

(10

)

 

(679

)

Comprehensive loss

$

(26,546

)

 

$

(24,428

)

 

$

(49,172

)

 

$

(44,322

)

 

 

 

 

 

 

 

 

Basic and diluted net loss per share

$

(1.50

)

 

$

(2.83

)

 

$

(3.44

)

 

$

(5.19

)

Shares used in computing basic and diluted net loss per share

18,142

 

 

8,446

 

 

14,280

 

 

8,411

 

Non-GAAP Reconciliations:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

Six Months Ended

 

June 30,

 

June 30,

 

2019

 

2018

 

2019

 

2018

Net Loss to Adjusted Net Loss:

 

 

 

 

 

 

Net loss

$

(27,134

)

 

$

(23,876

)

 

$

(49,162

)

 

$

(43,643

)

Fair value adjustment to Nellix contingent consideration
liability

300

 

 

1,800

 

 

100

 

 

700

 

Interest expense

8,857

 

 

5,861

 

 

17,347

 

 

11,665

 

Foreign currency loss

521

 

 

656

 

 

122

 

 

331

 

Restructuring and other transition costs

 

 

 

 

419

 

 

233

 

Fair value adjustment of derivative liabilities

(872

)

 

 

 

1,151

 

 

 

Loss on extinguishment of debt

11,756

 

 

 

 

11,756

 

 

2,270

 

(1) Adjusted Net Loss

$

(6,572

)

 

$

(15,559

)

 

$

(18,267

)

 

$

(28,444

)

 

 

 

 

 

 

 

 

Adjusted Net Loss to Adjusted EBITDA:

 

 

 

 

 

 

 

Adjusted Net Loss

$

(6,572

)

 

$

(15,559

)

 

$

(18,267

)

 

$

(28,444

)

Income tax (benefit) expense

(3,253

)

 

26

 

 

(3,214

)

 

111

 

Depreciation and amortization expense

1,740

 

 

1,939

 

 

3,475

 

 

3,931

 

Stock-based compensation expense

2,523

 

 

4,265

 

 

$

4,884

 

 

7,286

 

(2) Adjusted EBITDA

$

(5,562

)

 

$

(9,329

)

 

$

(13,122

)

 

$

(17,116

)

ENDOLOGIX, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

Unaudited

(In thousands)

 

June 30,

 

December 31,

 

2019

 

2018

ASSETS

 

 

 

Current assets:

 

 

 

Cash and cash equivalents

$

50,943

 

 

$

23,531

 

Restricted cash

1,200

 

 

1,200

 

Accounts receivable, net of allowance for doubtful accounts of $1,397 and $802, respectively

21,926

 

 

20,651

 

Other receivables

332

 

 

329

 

Inventories

30,747

 

 

30,399

 

Prepaid expenses and other current assets

2,270

 

 

2,821

 

Total current assets

107,418

 

 

78,931

 

Property and equipment, net

14,495

 

 

16,033

 

Goodwill

120,837

 

 

120,848

 

Other intangible assets, net

74,441

 

 

76,163

 

Deposits and other assets

1,372

 

 

1,095

 

Operating lease right-of-use assets

5,728

 

 

 

Total assets

$

324,291

 

 

$

293,070

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

Current liabilities:

 

 

 

Accounts payable

$

12,454

 

 

$

10,986

 

Accrued payroll

13,836

 

 

14,627

 

Accrued expenses and other current liabilities

16,241

 

 

13,314

 

Total current liabilities

42,531

 

 

38,927

 

Deferred income taxes

150

 

 

150

 

Deferred rent

 

 

8,065

 

Operating lease liabilities

11,812

 

 

 

Derivative liabilities

28,072

 

 

4,012

 

Other liabilities

2,326

 

 

1,992

 

Contingently issuable common stock

2,300

 

 

2,200

 

Debt

165,024

 

 

198,078

 

Total liabilities

252,215

 

 

253,424

 

Commitments and contingencies

 

 

 

Stockholders’ equity:

 

 

 

Convertible preferred stock, $0.001 par value, 5,000,000 shares authorized, no shares issued and
outstanding

 

 

 

Common stock, $0.001 par value, 170,000,000 and 170,000,000 shares authorized, respectively,
17,408,863 and 10,387,926 shares issued, respectively, and 17,352,698 and 10,345,367 shares
outstanding, respectively

17

 

 

10

 

Treasury stock, at cost, 56,165 and 42,559 shares, respectively

(4,120

)

 

(4,026

)

Additional paid-in capital

722,478

 

 

640,789

 

Accumulated deficit

(648,877

)

 

(599,715

)

Accumulated other comprehensive income

2,578

 

 

2,588

 

Total stockholders’ equity

72,076

 

 

39,646

 

Total liabilities and stockholders’ equity

$

324,291

 

 

$

293,070

 

 

CONTACT: INVESTORS:

Endologix, Inc.

Vaseem Mahboob, CFO

(949) 595-7200

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA

INDUSTRY KEYWORD: PROFESSIONAL SERVICES HEALTH MEDICAL DEVICES SURGERY FINANCE

SOURCE: Endologix, Inc.

Copyright Business Wire 2019.

PUB: 08/08/2019 04:01 PM/DISC: 08/08/2019 04:01 PM

Copyright Business Wire 2019.